移植物来源MAIT细胞免疫特征可预测胃肠道急性GVHD
本研究采用光谱流式细胞术表征外周血干细胞移植物中MAIT细胞的表型,发现移植物MAIT细胞丰度较高与移植后早期MAIT细胞重建更强及胃肠道急性GVHD风险较低相关。基于CCR2、IL-4、IL-17A三个功能标志物的预测模型AUC为0.80,校正临床协变量后升至0.85。
要点
- 移植物MAIT细胞丰度高与移植后早期重建更强、GI aGVHD风险更低相关
- CCR2、IL-4、IL-17A三标志物 panel 预测 GI aGVHD 的 AUC 为 0.80,校正后 0.85
- 移植物MAIT细胞可作为移植前风险分层与精准预防的免疫生物标志物
核心结论
- 移植物来源MAIT细胞是预测胃肠道急性GVHD的免疫相关生物标志物,支持移植前风险分层与精准预防。
研究设计与样本
- 前瞻性研究,采用光谱流式细胞术表征外周血干细胞移植物中MAIT细胞表型,试验注册号ChiCTR2500095349。
主要发现
- 移植物MAIT细胞丰度较高与移植后早期MAIT细胞重建更强及胃肠道急性GVHD风险较低相关。
- 基于MAIT细胞功能标志物CCR2、IL-4、IL-17A的三标志物预测panel的AUC为0.80,校正临床协变量后升至0.85。
关键数值与推荐
- 三标志物预测panel(CCR2、IL-4、IL-17A)预测GI aGVHD的AUC为0.80,校正临床协变量后为0.85。
临床怎么用
- 可在移植前检测移植物MAIT细胞丰度及CCR2、IL-4、IL-17A功能标志物,辅助识别胃肠道急性GVHD高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gastrointestinal acute graft-versus-host disease (GI aGVHD) remains a major complication after allogeneic haematopoietic stem cell transplantation (allo-HSCT), and early risk identification and intervention are essential for improving outcomes. Mucosal-associated invariant T (MAIT) cells are mucosa-enriched unconventional T cells with major histocompatibility complex class I-related protein 1 (MR1)-restricted, major histocompatibility complex (MHC)-independent recognition, suggesting a potentially reduced risk of alloreactivity. Our previous work showed that higher graft MAIT-cell levels were associated with improved post-transplant MAIT-cell reconstitution and a lower incidence of GI aGVHD. Single-cell ribonucleic acid (RNA) sequencing (sc-RNA-seq) and murine models revealed their functional heterogeneity in immune regulation, tissue repair and chemotaxis-supporting their role as both biomarkers and therapeutic targets. In this prospective study, spectral flow cytometry was used to characterize MAIT-cell phenotypes in peripheral blood stem cell grafts. higher graft MAIT-cell abundance was associated with more robust early post-transplant MAIT-cell reconstitution and a lower risk of GI aGVHD. A three-marker predictive panel based on MAIT-cell functional markers (C-C chemokine receptor type 2 [CCR2], interleukin-4 [IL-4], interleukin-17A [IL-17A]) achieved an area under the receiver operating characteristic curve (AUC) of 0.80, increasing to 0.85 after adjustment for clinical covariates. These findings identify graft-derived MAIT cells as a predictive immune-associated biomarker for GI aGVHD, enabling pre-transplant risk stratification and supporting precision prevention strategies. Trial registration: ChiCTR2500095349.
引用
- Mengge G, Rongqi C, Jun K, et al. Immune features of graft-derived mucosal-associated invariant T cells predict gastrointestinal graft-versus-host disease. Br J Haematol. 2026. PMID: 42458215. doi:10.1111/bjh.70683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。